References
- Greenberg PE, Arcelus A, Birnbaum HG et al Pharmacoeconomics and health policy: current applications and prospects for the future. PharmacoEconomics 16, 425–432 (1999).
- Byford S, Palmer S. Common errors and controversies in pharmacoeconomic analyses. PhatmacoEconomics 13,659–666 (1998).
- Mc Daid D, Cookson R. Evaluating healthcare interventions in the European Union. Health Pol. 63,133–139 (2003).
- Robinson R. Limits to rationality: economics, economists and priority setting. Health Pol. 49,13–26 (1999).
- Mooney G. What else do we want from our health services? Soc. Sc]. Merl 39, 151–154 (1994).
- Lazar° A. Theoretical arguments for the discounting of health consequences; where do we go from here? PharmacoEconomics 20,943–961 (2002).
- Cohen BJ. Discounting in cost-utility analysis of healthcare interventions: reassessing current practice. PharmacoEconomics 21(2), 75–87 (2003).
- Meltzer D, Johannesson M. Inconsistencies in the societal perspective on costs of the Panel on cost- effectiveness in health and medicine. Decis. Making 19(4), 371–377 (1999).
- Gravelle H, Smith DH. Discounting for health effects in cost-benefit and cost-effectiveness analysis. Health Econ. 10, 587–599 (2001).
- Mauskopf JA, Paul JE, Grant DM, Stergachis A. The role of cost-consequence analysis in healthcare decision-making. PharmacoEconomics 13(3), 277–288 (1998).
- Hoffman C, Graf von der Schulenburg JM. The influence of economic evaluation studies on decision making; a European survey. Health Pol. 52,179–192 (2000).
- Luce BR, Claxton K. Redefining the analytical approach to pharmacoeconomics. Health Econ. 8(3), 187–189 (1999).
- Zwart-van Rijkom JE, Leufkens HG, Busschbach JJ et al. Differences in attitudes, knowledge and use of economic evaluations in decision-making in The Netherlands. The Dutch results from the EUROMET Project. PharmacoEconomics 18(2), 149–160 (2000).
- Heitjan DE Fieller's method and net health benefits. Health Econ. 9,327–335 (2000).
- Liljas B, Lindgren B. On individual preferences and aggregation in economic evaluation in healthcare. PharmacoEconomics 19(4), 323–335 (2001).
- Johannesson M, Meltzer D. Some reflections on cost-effectiveness analysis. Health Econ. 7(1), 1–7 (1998).
- Johannesson M, O'Conor RM. Cost-utility analysis from a societal perspective. Health Pol. 39(3), 241–253 (1997).
- Alaska EM, Eisner M, Siegel C, Wanderling J. Statistical determination of cost-effectiveness frontier based on net health benefits. Health Econ. 11,249–264 (2002).
- van Hulst M, de Wolf JT, Staginnus U, Ruitenberg EJ, Postma MJ. Pharmacoeconomics of blood transfusion safety: review of the available evidence. Vox. Sang. 83(2), 146–155 (2002).
- Freemantle N. Valuing the effects of Sildenafil in erectile dysfunction. Strong assumptions are required to generate a QALY value. BE Med. 320(7243), 1156–1157 (2000).
- Donaldson C, ShacIdey P Does 'process utility' exist? A case study of willingness to pay for laparoscopic cholecystectomy. Soc. Sc]. Med. 44,699–707 (1997).
- Bos JM, Ramke HC, Welte R, Postma MJ. Epidemiological impact and cost-effectiveness of universal infant vaccination with a 7-valent conjugated pneumococcal vaccine in the Netherlands. Clin. Ther. 25,2614-2630 (2003).
- Birch S, Gafni A. Inclusion of drugs in provincial drug benefit programs: should 'reasonable' decisions lead to uncontrolled growth in expenditures? CMAJ168, 849–851 (2003).
- Gafni A, Birch S. Should cost-effectiveness take the blame? C11S4J168(12), 1528–1529 (2003).